Decades of History Tell Anything: Biotech Near $50 Set to Soar
A cash-generative biotech near $50 is drawing buyers amid a market shift toward defensible healthcare names. Here’s w...
Understanding when points offer greater value than cash back can enhance your credit card strategy. Discover these key moments.
28,161 articlesA cash-generative biotech near $50 is drawing buyers amid a market shift toward defensible healthcare names. Here’s w...
Want income that compounds over time? These high-yield energy stocks offer reliable payouts and growth potential. Lea...
A large hedge fund reduced its stake in InterDigital (IDCC) by selling 125,230 shares, worth about $44.28 million. Th...
Palantir delivers a strong Q1, beating expectations with better profitability than many software peers, yet the stock...
A notable fund exited its position in a medical device stock, locking in gains as the shares slipped over the past ye...
As Berkshire's new investment captain, Greg Abel faces a pivotal test: can his Q2 moves in Alphabet, Mitsubishi, Maru...
The beaten-down Figma shares rebound has investors weighing future growth, margins, and valuation. This guide breaks ...
A bold move from SpaceX has investors weighing risk and reward. This guide breaks down what the decision could mean f...
As market conditions shift, financial institutions are prioritizing customer value matters more to shape loan product...
As PDD Holdings gears up for its (pdd) 2026 earnings call, investors should focus on growth sustainability, margin pr...
When AI dominates headlines, investors often fear every software stock will crumble. This piece digs into whether fig...
One stock that's more than doubled in three years has turned heads in growth-focused portfolios. This article dives i...